NCT05849207View on ClinicalTrials.gov

Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant

PHASE1RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 24, 2023

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2028

Conditions
Hematologic Malignancies
Interventions
DRUG

Cyclophosphamide

Cyclophosphamide will be administered at 50, 40, 32, or 25 mg/k/d intravenous infusion (IV) continuously for two days starting 60-72 hours after transplant.

Trial Locations (1)

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

Ronald Paquette

OTHER